Business
from24/7 Wall St.
3 days agoForget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
Moderna faces declining revenue, cash burn, and binary catalysts, while Gilead offers steadier cash flow, dividend income, and stronger long-term franchise protection.